Q-omics provides the consensus-scored SETP9 profile across patient tissues and cancer cell-line models. SETP9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SETP9 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, SETP9 RNA expression shows 10,386 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where SETP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETP9 survival associations across molecular data types. SETP9 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETP9 RNA expression–survival associations across cancer types. High SETP9 expression shows unfavorable associations in KICH, ACC and KIRP, but favorable associations in HNSC, CHOL and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for SETP9 RNA expression.
This table summarizes SETP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SETP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETP9 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, STAD and LIHC. The KIRC box plot shows higher SETP9 RNA expression in tumor versus normal tissue (log2 FC = +0.074, t-test p < 0.001).
This table shows molecular features associated with SETP9 in patient tissues and cancer cell lines. In patient samples, SETP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
